A detailed history of Ubs Oconnor LLC transactions in Larimar Therapeutics, Inc. stock. As of the latest transaction made, Ubs Oconnor LLC holds 202,783 shares of LRMR stock, worth $657,016. This represents 0.09% of its overall portfolio holdings.

Number of Shares
202,783
Holding current value
$657,016
% of portfolio
0.09%

Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$6.3 - $10.68 $31,500 - $53,400
-5,000 Reduced 2.41%
202,783 $1.33 Million
Q2 2024

Aug 14, 2024

BUY
$6.33 - $9.89 $31,650 - $49,450
5,000 Added 2.47%
207,783 $1.51 Million
Q1 2024

May 15, 2024

SELL
$4.2 - $13.28 $491,895 - $1.56 Million
-117,118 Reduced 36.61%
202,783 $1.54 Million
Q4 2023

Feb 14, 2024

SELL
$2.35 - $4.71 $137,719 - $276,024
-58,604 Reduced 15.48%
319,901 $1.46 Million
Q3 2023

Nov 14, 2023

BUY
$3.08 - $4.49 $46,200 - $67,350
15,000 Added 4.13%
378,505 $1.5 Million
Q2 2023

Aug 14, 2023

BUY
$3.13 - $5.27 $1.14 Million - $1.92 Million
363,505 New
363,505 $1.14 Billion
Q1 2023

May 15, 2023

BUY
$4.0 - $6.68 $212,328 - $354,587
53,082 Added 33.3%
212,494 $962,000
Q4 2022

Feb 14, 2023

BUY
$2.73 - $5.08 $435,194 - $809,812
159,412 New
159,412 $0

Others Institutions Holding LRMR

About Larimar Therapeutics, Inc.


  • Ticker LRMR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,269,200
  • Market Cap $140M
  • Description
  • Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. T...
More about LRMR
Track This Portfolio

Track Ubs Oconnor LLC Portfolio

Follow Ubs Oconnor LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Oconnor LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Oconnor LLC with notifications on news.